Intravitreal ranibizumab monotherapy to treat XXXX zone II, stage 3 with plus disease.

@entity1 @entity11266 @entity2479 @entity989
BACKGROUND: Treatment of @entity989 ( @entity989 ) stage 3 plus with bevacizumab is still very controversial. We report the outcome of 6 eyes of 4 premature @entity1 with @entity989 stage 3 plus disease treated with ranibizumab monotherapy. METHODS: Six eyes of 4 premature @entity1 with threshold @entity989 3 plus disease in zone II, were treated with one intravitreal injection of 0.03  ml ranibizumab. No prior laser or other intravitreal therapy was done. Fundus examination was performed prior to the intervention and at each follow-up visit. Changes in various mean vital parameters one week post intervention compared to one week pre-intervention were assessed. RESULTS: The gestational age (GA) of @entity1 1, 2, 3, and 4 at birth was 24 5/7, 24 5/7, 24 4/7, and 26 1/7  weeks, respectively. The birth weight was 500 grams, 450 grams, 665 grams, and 745 grams, respectively. The GA at the date of treatment ranged from 34 3/7 to 38 6/7  weeks. In one @entity1 , upper air way infection was observed 2  days post injection of the second eye. Three eyes required paracentesis to reduce the intraocular pressure after injection and to restore central artery perfusion. After six months, all eyes showed @entity2479 without any signs of disease recurrence. CONCLUSIONS: Treatment of @entity989 3 plus disease with intravitreal ranibizumab was effective in all cases and should be considered for treatment. One @entity1 developed an upper air way infection suspicious for @entity11266 , which might be a possible side effect of ranibizumab. Another frequent complication was intraocular pressure rise after injection. More @entity1 with longer follow-up duration are mandatory to confirm the safety and efficacy of this treatment. TRIAL REGISTRATION NUMBER: NCT02164604 ; Date of registration: 13.06.2014.
